Akari Therapeutics, Plc (AKTX) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Akari Therapeutics, Plc (AKTX).

Download StockRank on Google Play Download StockRank on the App Store

Equity Overview

Price & Market Data

Price: $1.43

Daily Change: -$0.03 / 2.10%

Range: $1.43 - $1.48

Market Cap: $41,293,392

Volume: 2,519

Performance Metrics

1 Week: 18.67%

1 Month: 9.54%

3 Months: 23.52%

6 Months: -32.96%

1 Year: 18.18%

YTD: 17.21%

Company Details

Employees: 9

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Selected stocks

The OLB Group, Inc. (OLB)

Kodiak Sciences Inc. (KOD)

Agenus Inc. (AGEN)